ClinicalTrials.gov
public full text
Public Domain
Actium-225-Prostate Specific Membrane Antigen Imaging & Therapy
225Ac-PSMA I\&T is a radiopharmaceutical for therapy of prostate cancer. PSMA is overexpressed on prostate cancer cells. Actium-225 is an alpha emitting radionuclide. When PSMA I\&T is labelled with Actium-225, it can be applied as therapy for prostate cancer.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer#842122
- 68Ga-DOTA-Bombesin PET/MRI in Imaging Patients With Prostate Cancer#1127692
- Ga-68 Prostate Specific Membrane Antigen PET/CT in Gliomas#824942
- Correlation Between SPECT/CT and IDH Mutation in Brain Glioma#1127273
- The Value Of Delayed Imaging In Detection Of Recurrent Prostate Cancer Using Gallium-68 Prostate Specific Membrane Antigen (Psma) Positron Emission Tomography/computed Tomography (Pet/CT).#223717
Record · ID 889964
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive